[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Outcomes Following LVAD Implantation in Patients with Cancer: A Nationwide Analysis of Readmissions, Mortality, and Resource Utilization",
    "section": "",
    "text": "Reference Studies:\n\nAgrawal et al., 2018\n\nStudy Objective:\nTo identify patient- and hospital-level predictors of 30-day all-cause hospital readmission among adults patients with/without cancer undergoing LVAD implantation using a nationally representative dataset. This study also evaluates the clinical and economic burden of readmission in this high-risk population, including its association with in-hospital mortality.\nData Source:\nA retrospective cohort study using the 2019–2022 Nationwide Readmissions Database (NRD), developed by the Healthcare Cost and Utilization Project (HCUP). The NRD enables tracking of individual patients across hospitalizations within a given year via synthetic identifiers, capturing discharges from U.S. community hospitals and supporting survey-weighted national estimates through complex sampling design.\nCohort Definition:\nInclusion criteria:\n\nPatients aged &gt;= 18 years\nPatients who underwent LVAD implantation (ICD-10 PCS: 02HA0QZ)\nIndex discharge by the end of November to allow for a complete 30-day follow-up period\nComplete data on LOS and NRD_DAYSTOEVENT, required to compute discharge dates\n\nExclusion criteria:\n\nHeart transplant-related admissions\nPatients undergoing BiVAD implantation\nTrauma-related hospitalizations were excluded only from the readmission pool to avoid injury-related returns unrelated to the index LVAD hospitalization.\n\nExposure:\n\nThe primary exposure was cancer (ICD 10 CM: C00-C96)\n\nWith Cancer\nWithout Cancer\n\n\nCancer status was assessed only during the index hospitalization, not during readmissions.\nOutcomes:\n\nPrimary outcomes:\n\n30-day all-cause readmission\n\nSecondary outcomes:\n\nIn-hospital mortality during the index hospitalization\nLength of stay (LOS), measured in days\nInflation-adjusted total hospital charges, expressed in 2017 U.S. dollars\nNon-home discharge disposition (transfer, skilled nursing/intermediate facility, AMA, unknown destination, or in-hospital death)\nAcute kidney injury\nSepsis\nMajor bleed (Composite of GI bleed and intracranial hemorrhage)\n\nTop causes of cardiovascular readimssion\n\nCovariates:\n\nDemographics: age, sex, primary expected payer and median household income quartile by ZIP code.\nClinical characteristics: Elixhauser comorbidity index, length of stay, non-home discharge.\nHospital characteristics: hospital bed size, and hospital location/teaching.\n\nStatistical Methods:\n\nSurvey Design and Weighting:\n\nAll analyses incorporated NRD’s complex sampling design via the survey and srvyr packages.\n\nDescriptive Statistics:\n\nWeighted baseline characteristics of index hospitalizations were summarized and stratified by cancer status to compare those with vs without cancer.\nP-values from statistical tests (Rao–Scott adjusted chi-square for categorical variables; Kruskal–Wallis test for continuous variables).\n\nMultivariable Regression:\n\nA survey-weighted logistic regression modeled predictors of 30-day readmission.\nThe model included demographic, clinical, hospital-level, and index-stay factors.\nResults were exponentiated to yield odds ratios (ORs) with 95% confidence intervals.\n\n\nSoftware: All analyses were conducted in R Statistical Language (Version 4.5.0; R Foundation for Statistical Computing, Vienna, Austria)."
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Outcomes Following LVAD Implantation in Patients with Cancer: A Nationwide Analysis of Readmissions, Mortality, and Resource Utilization",
    "section": "",
    "text": "Reference Studies:\n\nAgrawal et al., 2018\n\nStudy Objective:\nTo identify patient- and hospital-level predictors of 30-day all-cause hospital readmission among adults patients with/without cancer undergoing LVAD implantation using a nationally representative dataset. This study also evaluates the clinical and economic burden of readmission in this high-risk population, including its association with in-hospital mortality.\nData Source:\nA retrospective cohort study using the 2019–2022 Nationwide Readmissions Database (NRD), developed by the Healthcare Cost and Utilization Project (HCUP). The NRD enables tracking of individual patients across hospitalizations within a given year via synthetic identifiers, capturing discharges from U.S. community hospitals and supporting survey-weighted national estimates through complex sampling design.\nCohort Definition:\nInclusion criteria:\n\nPatients aged &gt;= 18 years\nPatients who underwent LVAD implantation (ICD-10 PCS: 02HA0QZ)\nIndex discharge by the end of November to allow for a complete 30-day follow-up period\nComplete data on LOS and NRD_DAYSTOEVENT, required to compute discharge dates\n\nExclusion criteria:\n\nHeart transplant-related admissions\nPatients undergoing BiVAD implantation\nTrauma-related hospitalizations were excluded only from the readmission pool to avoid injury-related returns unrelated to the index LVAD hospitalization.\n\nExposure:\n\nThe primary exposure was cancer (ICD 10 CM: C00-C96)\n\nWith Cancer\nWithout Cancer\n\n\nCancer status was assessed only during the index hospitalization, not during readmissions.\nOutcomes:\n\nPrimary outcomes:\n\n30-day all-cause readmission\n\nSecondary outcomes:\n\nIn-hospital mortality during the index hospitalization\nLength of stay (LOS), measured in days\nInflation-adjusted total hospital charges, expressed in 2017 U.S. dollars\nNon-home discharge disposition (transfer, skilled nursing/intermediate facility, AMA, unknown destination, or in-hospital death)\nAcute kidney injury\nSepsis\nMajor bleed (Composite of GI bleed and intracranial hemorrhage)\n\nTop causes of cardiovascular readimssion\n\nCovariates:\n\nDemographics: age, sex, primary expected payer and median household income quartile by ZIP code.\nClinical characteristics: Elixhauser comorbidity index, length of stay, non-home discharge.\nHospital characteristics: hospital bed size, and hospital location/teaching.\n\nStatistical Methods:\n\nSurvey Design and Weighting:\n\nAll analyses incorporated NRD’s complex sampling design via the survey and srvyr packages.\n\nDescriptive Statistics:\n\nWeighted baseline characteristics of index hospitalizations were summarized and stratified by cancer status to compare those with vs without cancer.\nP-values from statistical tests (Rao–Scott adjusted chi-square for categorical variables; Kruskal–Wallis test for continuous variables).\n\nMultivariable Regression:\n\nA survey-weighted logistic regression modeled predictors of 30-day readmission.\nThe model included demographic, clinical, hospital-level, and index-stay factors.\nResults were exponentiated to yield odds ratios (ORs) with 95% confidence intervals.\n\n\nSoftware: All analyses were conducted in R Statistical Language (Version 4.5.0; R Foundation for Statistical Computing, Vienna, Austria)."
  },
  {
    "objectID": "quarto/index.html#descriptive-analyses",
    "href": "quarto/index.html#descriptive-analyses",
    "title": "Outcomes Following LVAD Implantation in Patients with Cancer: A Nationwide Analysis of Readmissions, Mortality, and Resource Utilization",
    "section": "Descriptive Analyses",
    "text": "Descriptive Analyses\n\nBaseline Characteristics\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 12,4251\nWithout Cancer\nN = 11,3101\nWith Cancer\nN = 1,1141\np-value2\n\n\n\n\nAge (years)\n57 (13)\n57 (13)\n56 (13)\n0.5\n\n\nSex\n\n\n\n\n\n\n0.8\n\n\n    Male\n9,464 (76%)\n8,619 (76%)\n845 (76%)\n\n\n\n\n    Female\n2,961 (24%)\n2,691 (24%)\n270 (24%)\n\n\n\n\nInsurance\n\n\n\n\n\n\n0.3\n\n\n    Private\n3,897 (31%)\n3,505 (31%)\n391 (35%)\n\n\n\n\n    Medicaid\n2,183 (18%)\n1,993 (18%)\n190 (17%)\n\n\n\n\n    Medicare\n5,801 (47%)\n5,306 (47%)\n495 (44%)\n\n\n\n\n    Other\n535 (4.3%)\n496 (4.4%)\n38 (3.4%)\n\n\n\n\nMedian Income Quartile\n\n\n\n\n\n\n0.2\n\n\n    0-25th percentile\n4,072 (33%)\n3,741 (33%)\n330 (30%)\n\n\n\n\n    26th to 50th percentile\n3,479 (28%)\n3,182 (28%)\n297 (27%)\n\n\n\n\n    51st to 75th percentile\n2,811 (23%)\n2,523 (22%)\n288 (26%)\n\n\n\n\n    76th to 100th percentile\n1,975 (16%)\n1,783 (16%)\n192 (17%)\n\n\n\n\nHospital Bed Size\n\n\n\n\n\n\n0.5\n\n\n    Small\n222 (1.8%)\n209 (1.8%)\n14 (1.2%)\n\n\n\n\n    Large\n11,357 (91%)\n10,328 (91%)\n1,029 (92%)\n\n\n\n\n    Medium\n845 (6.8%)\n774 (6.8%)\n72 (6.5%)\n\n\n\n\nHospital Teaching Status\n\n\n\n\n\n\n0.2\n\n\n    Metropolitan, non-teaching\n103 (0.8%)\n99 (0.9%)\n4 (0.4%)\n\n\n\n\n    Metropolitan, teaching\n12,322 (99%)\n11,211 (99%)\n1,110 (100%)\n\n\n\n\nElixhauser's Comorbidity Index\n7.73 (2.33)\n7.67 (2.34)\n8.26 (2.13)\n&lt;0.001\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment\n\n\n\n\n\n\n\n\n\n\nOutcomes of Index Hospitalizations\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 12,4251\nWithout Cancer\nN = 11,3101\nWith Cancer\nN = 1,1141\np-value2\n\n\n\n\n30-Day Readmission\n1,681 (14%)\n1,518 (13%)\n163 (15%)\n0.5\n\n\nIn-Hospital Mortality\n1,534 (12%)\n1,422 (13%)\n112 (10%)\n0.081\n\n\nLength of Stay (days)\n34 (23, 51)\n33 (23, 50)\n43 (30, 63)\n&lt;0.001\n\n\nInflation-Adjusted Total Charges ($)\n1,013,629 (736,673, 1,535,092)\n999,303 (727,156, 1,505,717)\n1,192,509 (869,794, 1,784,044)\n&lt;0.001\n\n\nNon Home Discharge\n4,005 (32%)\n3,641 (32%)\n364 (33%)\n0.8\n\n\nAcute kidney injury\n9,356 (75%)\n8,409 (74%)\n948 (85%)\n&lt;0.001\n\n\nSepsis\n2,241 (18%)\n1,963 (17%)\n278 (25%)\n&lt;0.001\n\n\nMajor bleed\n1,306 (11%)\n1,172 (10%)\n135 (12%)\n0.3\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Outcomes Following LVAD Implantation in Patients with Cancer: A Nationwide Analysis of Readmissions, Mortality, and Resource Utilization",
    "section": "Multivariable Logistic Regression",
    "text": "Multivariable Logistic Regression\n\nPredictors of 30-Day Readmission\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nCancer\n\n\n\n\n\n\n\n\n    Without Cancer\n—\n—\n\n\n\n\n    With Cancer\n1.05\n0.80, 1.38\n0.7\n\n\nAge (years)\n1.00\n1.00, 1.01\n0.4\n\n\nSex\n\n\n\n\n\n\n\n\n    Male\n—\n—\n\n\n\n\n    Female\n1.09\n0.89, 1.33\n0.4\n\n\nInsurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.41\n1.13, 1.76\n0.002\n\n\n    Medicare\n1.38\n1.15, 1.66\n&lt;0.001\n\n\n    Other\n1.09\n0.66, 1.79\n0.7\n\n\nMedian Income Quartile\n\n\n\n\n\n\n\n\n    0-25th percentile\n—\n—\n\n\n\n\n    26th to 50th percentile\n0.92\n0.76, 1.11\n0.4\n\n\n    51st to 75th percentile\n1.01\n0.81, 1.26\n&gt;0.9\n\n\n    76th to 100th percentile\n0.92\n0.72, 1.19\n0.5\n\n\nHospital Bed Size\n\n\n\n\n\n\n\n\n    Small\n—\n—\n\n\n\n\n    Large\n1.01\n0.69, 1.48\n&gt;0.9\n\n\n    Medium\n0.81\n0.49, 1.33\n0.4\n\n\nHospital Teaching Status\n\n\n\n\n\n\n\n\n    Metropolitan, non-teaching\n—\n—\n\n\n\n\n    Metropolitan, teaching\n0.76\n0.28, 2.10\n0.6\n\n\nElixhauser's Comorbidity Index\n1.04\n1.01, 1.08\n0.022\n\n\nLength of Stay (days)\n1.00\n1.00, 1.01\n&lt;0.001\n\n\nNon Home Discharge\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.69\n0.56, 0.85\n&lt;0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nAcute kidney injury:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nCancer\n\n\n\n\n\n\n\n\n    Without Cancer\n—\n—\n\n\n\n\n    With Cancer\n1.51\n1.15, 1.98\n0.003\n\n\nAge (years)\n0.99\n0.99, 1.00\n0.006\n\n\nSex\n\n\n\n\n\n\n\n\n    Male\n—\n—\n\n\n\n\n    Female\n0.63\n0.55, 0.72\n&lt;0.001\n\n\nInsurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.85\n0.68, 1.07\n0.2\n\n\n    Medicare\n0.89\n0.75, 1.06\n0.2\n\n\n    Other\n0.92\n0.67, 1.27\n0.6\n\n\nMedian Income Quartile\n\n\n\n\n\n\n\n\n    0-25th percentile\n—\n—\n\n\n\n\n    26th to 50th percentile\n1.05\n0.89, 1.24\n0.5\n\n\n    51st to 75th percentile\n1.16\n0.96, 1.41\n0.13\n\n\n    76th to 100th percentile\n1.21\n0.95, 1.54\n0.12\n\n\nHospital Bed Size\n\n\n\n\n\n\n\n\n    Small\n—\n—\n\n\n\n\n    Large\n0.99\n0.43, 2.25\n&gt;0.9\n\n\n    Medium\n1.00\n0.42, 2.36\n&gt;0.9\n\n\nHospital Teaching Status\n\n\n\n\n\n\n\n\n    Metropolitan, non-teaching\n—\n—\n\n\n\n\n    Metropolitan, teaching\n1.66\n0.73, 3.74\n0.2\n\n\nElixhauser's Comorbidity Index\n1.23\n1.15, 1.31\n&lt;0.001\n\n\nLength of Stay (days)\n1.02\n1.02, 1.03\n&lt;0.001\n\n\nNon Home Discharge\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.15\n1.81, 2.55\n&lt;0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nSepsis:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nCancer\n\n\n\n\n\n\n\n\n    Without Cancer\n—\n—\n\n\n\n\n    With Cancer\n1.32\n1.00, 1.74\n0.050\n\n\nAge (years)\n0.98\n0.97, 0.99\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Male\n—\n—\n\n\n\n\n    Female\n0.75\n0.61, 0.93\n0.007\n\n\nInsurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.94\n0.71, 1.23\n0.6\n\n\n    Medicare\n0.97\n0.78, 1.21\n0.8\n\n\n    Other\n0.94\n0.64, 1.38\n0.7\n\n\nMedian Income Quartile\n\n\n\n\n\n\n\n\n    0-25th percentile\n—\n—\n\n\n\n\n    26th to 50th percentile\n0.84\n0.65, 1.09\n0.2\n\n\n    51st to 75th percentile\n0.91\n0.73, 1.14\n0.4\n\n\n    76th to 100th percentile\n1.13\n0.89, 1.43\n0.3\n\n\nHospital Bed Size\n\n\n\n\n\n\n\n\n    Small\n—\n—\n\n\n\n\n    Large\n1.30\n0.82, 2.08\n0.3\n\n\n    Medium\n1.49\n0.89, 2.49\n0.13\n\n\nHospital Teaching Status\n\n\n\n\n\n\n\n\n    Metropolitan, non-teaching\n—\n—\n\n\n\n\n    Metropolitan, teaching\n1.21\n0.53, 2.77\n0.7\n\n\nElixhauser's Comorbidity Index\n0.97\n0.92, 1.01\n0.15\n\n\nLength of Stay (days)\n1.03\n1.02, 1.03\n&lt;0.001\n\n\nNon Home Discharge\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n4.12\n3.51, 4.83\n&lt;0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nMajor Bleed\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nCancer\n\n\n\n\n\n\n\n\n    Without Cancer\n—\n—\n\n\n\n\n    With Cancer\n1.03\n0.70, 1.49\n0.9\n\n\nAge (years)\n1.01\n1.00, 1.01\n0.2\n\n\nSex\n\n\n\n\n\n\n\n\n    Male\n—\n—\n\n\n\n\n    Female\n1.06\n0.83, 1.37\n0.6\n\n\nInsurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.99\n0.74, 1.32\n&gt;0.9\n\n\n    Medicare\n0.94\n0.76, 1.16\n0.6\n\n\n    Other\n1.52\n1.04, 2.21\n0.030\n\n\nMedian Income Quartile\n\n\n\n\n\n\n\n\n    0-25th percentile\n—\n—\n\n\n\n\n    26th to 50th percentile\n1.03\n0.84, 1.27\n0.7\n\n\n    51st to 75th percentile\n1.07\n0.83, 1.37\n0.6\n\n\n    76th to 100th percentile\n1.02\n0.79, 1.33\n0.9\n\n\nHospital Bed Size\n\n\n\n\n\n\n\n\n    Small\n—\n—\n\n\n\n\n    Large\n0.61\n0.38, 0.99\n0.047\n\n\n    Medium\n0.53\n0.30, 0.94\n0.030\n\n\nHospital Teaching Status\n\n\n\n\n\n\n\n\n    Metropolitan, non-teaching\n—\n—\n\n\n\n\n    Metropolitan, teaching\n2.51\n0.85, 7.41\n0.10\n\n\nElixhauser's Comorbidity Index\n1.01\n0.96, 1.05\n0.8\n\n\nLength of Stay (days)\n1.01\n1.01, 1.02\n&lt;0.001\n\n\nNon Home Discharge\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.84\n2.31, 3.48\n&lt;0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Outcomes Following LVAD Implantation in Patients with Cancer: A Nationwide Analysis of Readmissions, Mortality, and Resource Utilization",
    "section": "Multivariable Linear Regression",
    "text": "Multivariable Linear Regression\n\nLength of Stay\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nCancer\n\n\n\n\n\n\n\n\n    Without Cancer\n—\n—\n\n\n\n\n    With Cancer\n8.6\n5.9, 11\n&lt;0.001\n\n\nAge (years)\n-0.10\n-0.17, -0.03\n0.006\n\n\nSex\n\n\n\n\n\n\n\n\n    Male\n—\n—\n\n\n\n\n    Female\n1.4\n-0.38, 3.1\n0.12\n\n\nInsurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n-0.51\n-2.7, 1.7\n0.6\n\n\n    Medicare\n-1.5\n-3.5, 0.44\n0.13\n\n\n    Other\n-2.8\n-7.7, 2.2\n0.3\n\n\nMedian Income Quartile\n\n\n\n\n\n\n\n\n    0-25th percentile\n—\n—\n\n\n\n\n    26th to 50th percentile\n-1.2\n-3.2, 0.79\n0.2\n\n\n    51st to 75th percentile\n-0.40\n-2.6, 1.8\n0.7\n\n\n    76th to 100th percentile\n1.8\n-0.66, 4.3\n0.2\n\n\nHospital Bed Size\n\n\n\n\n\n\n\n\n    Small\n—\n—\n\n\n\n\n    Large\n8.5\n1.6, 15\n0.016\n\n\n    Medium\n5.7\n-1.8, 13\n0.13\n\n\nHospital Teaching Status\n\n\n\n\n\n\n\n\n    Metropolitan, non-teaching\n—\n—\n\n\n\n\n    Metropolitan, teaching\n3.9\n0.97, 6.7\n0.009\n\n\nElixhauser's Comorbidity Index\n1.4\n0.94, 1.8\n&lt;0.001\n\n\nNon Home Discharge\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n12\n10, 15\n&lt;0.001\n\n\n\nAbbreviation: CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation-adjusted Total Charge\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nCancer\n\n\n\n\n\n\n\n\n    Without Cancer\n—\n—\n\n\n\n\n    With Cancer\n19,644\n-55,435, 94,723\n0.6\n\n\nAge (years)\n-2,772\n-4,392, -1,153\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Male\n—\n—\n\n\n\n\n    Female\n-62,594\n-101,348, -23,839\n0.002\n\n\nInsurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n765\n-54,529, 56,059\n&gt;0.9\n\n\n    Medicare\n-58,392\n-104,779, -12,006\n0.014\n\n\n    Other\n-83,557\n-206,884, 39,769\n0.2\n\n\nMedian Income Quartile\n\n\n\n\n\n\n\n\n    0-25th percentile\n—\n—\n\n\n\n\n    26th to 50th percentile\n59,595\n14,378, 104,811\n0.010\n\n\n    51st to 75th percentile\n41,415\n-10,591, 93,420\n0.12\n\n\n    76th to 100th percentile\n189,184\n104,662, 273,706\n&lt;0.001\n\n\nHospital Bed Size\n\n\n\n\n\n\n\n\n    Small\n—\n—\n\n\n\n\n    Large\n-8,633\n-255,565, 238,299\n&gt;0.9\n\n\n    Medium\n13,274\n-257,604, 284,153\n&gt;0.9\n\n\nHospital Teaching Status\n\n\n\n\n\n\n\n\n    Metropolitan, non-teaching\n—\n—\n\n\n\n\n    Metropolitan, teaching\n-153,840\n-461,129, 153,450\n0.3\n\n\nElixhauser's Comorbidity Index\n5,383\n-8,118, 18,884\n0.4\n\n\nLength of Stay (days)\n18,547\n16,603, 20,490\n&lt;0.001\n\n\nNon Home Discharge\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n254,464\n179,850, 329,078\n&lt;0.001\n\n\n\nAbbreviation: CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#top-cardiovascular-causes-of-readmission",
    "href": "quarto/index.html#top-cardiovascular-causes-of-readmission",
    "title": "Outcomes Following LVAD Implantation in Patients with Cancer: A Nationwide Analysis of Readmissions, Mortality, and Resource Utilization",
    "section": "Top cardiovascular causes of readmission:",
    "text": "Top cardiovascular causes of readmission:\n\n\n\n\n\n\n\n\n\nRank\nICD-10 Code\nCardiovascular Diagnosis\nProportion\n\n\n\n\n1\nI13\nHypertensive heart and renal disease\n0.112\n\n\n2\nI11\nHypertensive heart disease\n0.0638\n\n\n3\nI47\nParoxysmal tachycardia\n0.0611\n\n\n4\nI50\nHeart failure\n0.0463\n\n\n5\nI95\nHypotension\n0.0179\n\n\n6\nI48\nAtrial fibrillation and flutter\n0.0100\n\n\n7\nI49\nOther cardiac arrhythmias\n0.00953\n\n\n8\nI63\nCerebral infarction\n0.00911\n\n\n9\nI42\nCardiomyopathy\n0.00707\n\n\n10\nI25\nChronic ischemic heart disease\n0.00639"
  }
]